Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales. In final guidance ...

Treatment with nivolumab reduced the risk of disease recurrence, progression or death by 42% compared with placebo. The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with ...

Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure rate advantage ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

BMY’s Opdivo is one of the leading immuno-oncology ... The board of directors has authorized the repurchase of up to an additional $500 million of the company’s common stock through the ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC). These adult patients ...

Keytruda, Opdivo, and Tencentriq are all blockbuster drugs that shrink ... In early 2023, it handed Akeso $500 million ...

The company’s top-selling drugs of 2022 include cancer therapies Revlimid and Opdivo and anticoagulant Eliquis. Bristol-Myers’ fourth-quarter earnings per share beat Wall Street expectations ...

The profitability screen requires that the sum of a company’s GAAP earnings over the past four quarters be positive as well as the most recent quarter. The screen imparts a slight quality tilt ...

The company’s top-selling drugs of 2022 include cancer therapies Revlimid and Opdivo and anticoagulant Eliquis. Bristol-Myers’ fourth-quarter earnings per share beat Wall Street expectations ...

If you type “laptops under $500” into any search bar, you’ll be faced with a flood of results. Although you’ll see a lot of options, most aren’t worth the price, no matter the discount.